Efficacy of Loratadine Compared with Fexofenadine or Placebo for the Treatment of Seasonal Allergic Rhinitis

Harold B. Kaiser, Clinical Research Institute, Minneapolis, Minnesota, USA; Anthony Rooklin, Allergy Research Associates, Media, Pennsylvania, USA; Dennis Spangler, Atlanta Allergy & Immunology Research Foundation, Atlanta, Georgia; David Capano, Integrated Therapeutics Group, Inc., New Jersey, USA

Clin Drug Invest. 2001;21(8) 

In This Article


Loratadine and fexofenadine were superior to placebo in reducing the symptoms of SAR. Compared with fexofenadine, loratadine provided significantly greater relief in symptoms of SAR at four of the first five time-points evaluated during the first 3 days of treatment and achieved a maximum treatment efficacy earlier after the initiation of therapy than fexofenadine. Significant symptomatic benefit was seen with loratadine (versus both placebo and fexofenadine) at the first assessment (day 1 pm, 12 hours after the first dose). Because individuals frequently use antihistamines on an as-needed basis for symptomatic relief of SAR, the greater degree of early symptom relief seen with loratadine is a desirable characteristic in its practical use.